Stammdaten
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Unternehmen & Branche
| Name | HCW Biologics Inc. |
|---|---|
| Ticker | HCWB |
| CIK | 0001828673 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 843.099 USD |
| Beta | 0,91 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -7,959,709 | -10.63 | 24,520,013 | 2,764,769 | |
| 2025-09-30 | 10-Q | -4,554,336 | -2.02 | 25,445,540 | -2,107,197 | |
| 2025-06-30 | 10-Q | -1,927,730 | -6.79 | 28,909,636 | -51,972 | |
| 2025-03-31 | 10-Q | -2,196,875 | -0.05 | 26,285,406 | -8,562,048 | |
| 2024-12-31 | 10-K | -30,023,814 | -30.96 | 30,236,578 | -6,770,172 | |
| 2024-09-30 | 10-Q | -3,902,288 | -4.13 | 26,556,479 | -9,969,624 | |
| 2024-06-30 | 10-Q | -15,280,191 | -16.16 | 26,820,091 | -6,299,769 | |
| 2024-03-31 | 10-Q | -7,468,061 | -0.20 | 30,427,656 | 8,740,601 | |
| 2023-12-31 | 10-K | -24,994,277 | -0.70 | 28,513,660 | 13,461,717 | |
| 2023-09-30 | 10-Q | -4,938,641 | -0.14 | 35,616,342 | 23,866,933 | |
| 2023-06-30 | 10-Q | -4,304,420 | -0.12 | 39,483,244 | 28,585,642 | |
| 2023-03-31 | 10-Q | -5,070,686 | -0.14 | 43,534,545 | 32,618,927 | |
| 2022-12-31 | 10-K | -14,900,703 | -0.42 | 46,809,155 | 37,428,506 | |
| 2022-09-30 | 10-Q | -3,914,194 | -0.11 | 51,353,202 | 42,555,228 | |
| 2022-06-30 | 10-Q | -3,510,561 | -0.10 | 47,408,422 | 46,165,428 | |
| 2022-03-31 | 10-Q | -2,057,207 | -0.06 | 50,955,667 | 49,398,654 | |
| 2021-12-31 | 10-K | -12,862,468 | -0.69 | 53,514,829 | 51,193,240 | |
| 2021-09-30 | 10-Q | 0 | -4,094,704 | -0.14 | 56,405,950 | 54,011,448 |
| 2021-06-30 | 10-Q | 0 | -2,750,362 | -0.66 | 13,033,394 | -23,239,702 |
| 2021-03-31 | 10-Q | -2,843,996 | -20,025,725 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | GARRETT SCOTT T | Director | Open Market Purchase | 13,423 | 7.45 | 100,001.35 | +83,3% | |
| 2025-05-08 | GARRETT SCOTT T | Director | Open Market Purchase | 5,385 | 26.00 | 140,010.00 | +116,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.